September 29, 2010, marks the 10th anniversary of Food and Drug Administration's approval
of Mifeprex (mifepristone) in the United States. That moment 10 years ago brought
women the promise of increased access to early, safe, noninvasive abortion and the
potential mainstreaming of abortion services into the larger scope of routine comprehensive
women's health care [
1
,
2
]. The arduous 12-year path to approval required an intensive level of collaboration
among key professional, advocacy and research organizations, working closely to navigate
abortion-related politics and meet the natural challenges of introducing a new medical
option to women and their health care providers.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Can mifepristone medical abortion be simplified? A review of the evidence and questions for future research.Contraception. 2007; 75: 245-250
- Effect of mifepristone on abortion access in the United States.Obstet Gynecol. 2009; 114: 623-630
- Abortion access in the United States: incidence and access to services, 2005.Perspec Sex Reproduc Health. 2008; 40: 6-16
- Mifepristone: ten years later.Contraception. 2010; 81: 1-7
Article info
Publication history
Published online: July 21, 2010
Identification
Copyright
© 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
